January 9, 2017
Argenx starts Phase II study of myasthenia gravis drug
Argenx, a European biopharmaceutical company focused on drugs for the treatment of cancer and autoimmune diseases, has initiated a Phase…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
January 9, 2017
Celyad’s patent holds up after being challenged by third party
U.S. Patent and Trade Office (USPTO) has decided to uphold Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary…
January 9, 2017
Why study Bioscience?
Author: Anna Michael, The Study Abroad Portal The Study Abroad Portal helps students worldwide to make the right decision with…
January 9, 2017
Ipsen buys Merrimack’s oncology assets
Ipsen has acquired global oncology assets from Merrimack Pharmaceuticals. This acquisition includes Merrimack’s key marketed product Onivyde (irinotecan liposome injection)…
January 9, 2017
e-Therapeutics finds CEO in Amgen
e-Therapeutics plc, the drug discovery company, has made further steps in transitioning its business as it picked Amgen Inc.’s Corporate Development Executive Director, Dr. Raymond Barlow as its new Chief Executive Officer (CEO) who assume his position before May 1, 2017.
January 9, 2017
AB Sciences’ masitinib gets new validations
AB Sciences has more reasons to believe that its protein kinase inhibitor (PKI) masitinib could have FDA’s further clearence, as the results from the pivotal phase 3 study have been published in highly regarded independent general medical journal, The Lancet.
January 6, 2017
BMS tries out GeneCentric’s Cancer Subtype Platform for Opdivo clinical trials
Bristol-Myers Squibb (BMS) and GeneCentric Diagnostics have teamed up to explore the possibility of GeneCentric’s Cancer Subtype Platform (CSP) could identify translational biomakers for Opdivo, that could help for future clinical trials.
January 6, 2017
Novartis and Ionis team on cardiovascular treatments
Novartis and Ionis Pharmaceuticals with its affiliate Akcea Therapeutics have signed an agreement for licensing two novel treatments for reducing cardiovascular risk in patients with high levels of lipoproteins known as Lp(a) and ApoCIII.
January 6, 2017
Sanofi, Regeneron to appeal on Praluent ban in the U.S. due to two Amgen patents
Sanofi and Regeneron Pharmaceuticals are going to will appeal the injunction granted on Friday by the U.S. District Court for the District of Delaware preventing the marketing, selling or manufacturing of Praluent in the U.S. during the term of two Amgen patents.
January 6, 2017
Shield’s iron deficiency anaemia drug kicks off well in Europe
Shield Therapeutics said it was encouraged by the the demand of its its recently approved product for the treatment of iron…